Hyperspectral Imaging in Major Hepatectomies: Preliminary Results from the Ex-Machyna Trial.
Fiche publication
Date publication
novembre 2022
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MARESCAUX Jacques, Pr PESSAUX Patrick, Pr MUTTER Didier
Tous les auteurs :
Felli E, Cinelli L, Bannone E, Giannone F, Muttillo EM, Barberio M, Keller DS, Rodríguez-Luna MR, Okamoto N, Collins T, Hostettler A, Schuster C, Mutter D, Pessaux P, Marescaux J, Gioux S, Felli E, Diana M
Lien Pubmed
Résumé
Ischemia-reperfusion injury during major hepatic resections is associated with high rates of post-operative complications and liver failure. Real-time intra-operative detection of liver dysfunction could provide great insight into clinical outcomes. In the present study, we demonstrate the intra-operative application of a novel optical technology, hyperspectral imaging (HSI), to predict short-term post-operative outcomes after major hepatectomy. We considered fifteen consecutive patients undergoing major hepatic resection for malignant liver lesions from January 2020 to June 2021. HSI measures included tissue water index (TWI), organ hemoglobin index (OHI), tissue oxygenation (StO%), and near infrared (NIR). Pre-operative, intra-operative, and post-operative serum and clinical outcomes were collected. NIR values were higher in unhealthy liver tissue ( = 0.003). StO% negatively correlated with post-operative serum ALT values ( = -0.602), while ΔStO% positively correlated with ALP ( = 0.594). TWI significantly correlated with post-operative reintervention and OHI with post-operative sepsis and liver failure. In conclusion, the HSI imaging system is accurate and precise in translating from pre-clinical to human studies in this first clinical trial. HSI indices are related to serum and outcome metrics. Further experimental and clinical studies are necessary to determine clinical value of this technology.
Mots clés
hepatectomy, hyperspectral imaging, image-guided surgery, major hepatectomy, post-hepatectomy liver failure (PHLF)
Référence
Cancers (Basel). 2022 11 14;14(22):